Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 17 de 17
1.
ACS Nano ; 18(17): 11284-11299, 2024 Apr 30.
Article En | MEDLINE | ID: mdl-38639114

The development of mRNA delivery systems utilizing lipid-based assemblies holds immense potential for precise control of gene expression and targeted therapeutic interventions. Despite advancements in lipid-based gene delivery systems, a critical knowledge gap remains in understanding how the biophysical characteristics of lipid assemblies and mRNA complexes influence these systems. Herein, we investigate the biophysical properties of cationic liposomes and their role in shaping mRNA lipoplexes by comparing various fabrication methods. Notably, an innovative fabrication technique called the liposome under cryo-assembly (LUCA) cycle, involving a precisely controlled freeze-thaw-vortex process, produces distinctive onion-like concentric multilamellar structures in cationic DOTAP/DOPE liposomes, in contrast to a conventional extrusion method that yields unilamellar liposomes. The inclusion of short-chain DHPC lipids further modulates the structure of cationic liposomes, transforming them from multilamellar to unilamellar structures during the LUCA cycle. Furthermore, the biophysical and biological evaluations of mRNA lipoplexes unveil that the optimal N/P charge ratio in the lipoplex can vary depending on the structure of initial cationic liposomes. Cryo-EM structural analysis demonstrates that multilamellar cationic liposomes induce two distinct interlamellar spacings in cationic lipoplexes, emphasizing the significant impact of the liposome structures on the final structure of mRNA lipoplexes. Taken together, our results provide an intriguing insight into the relationship between lipid assembly structures and the biophysical characteristics of the resulting lipoplexes. These relationships may open the door for advancing lipid-based mRNA delivery systems through more streamlined manufacturing processes.


Fatty Acids, Monounsaturated , Lipids , Liposomes , Quaternary Ammonium Compounds , RNA, Messenger , Liposomes/chemistry , RNA, Messenger/chemistry , RNA, Messenger/genetics , Lipids/chemistry , Humans , Gene Transfer Techniques , Phosphatidylethanolamines/chemistry
2.
J Hazard Mater ; 435: 128980, 2022 08 05.
Article En | MEDLINE | ID: mdl-35523089

The ingestion and accumulation of microplastics is a serious threat to the health and survival of humans and other organisms given the increasing use of daily-use plastic products, especially during the COVID-19 pandemic. However, whether direct microplastic contamination from plastic packaging is a threat to human health remains unclear. We analyzed the market demand for plastic packaging in Asia-Pacific, North America, and Europe and identified the commonly used plastic food packaging products. We found that food containers exposed to high-temperature released more than 10 million microplastics per mL in water. Recycled plastic food packaging was demonstrated to continuously leach micro- and nanoplastics. In vitro cell engulfing experiments revealed that both micro- and nanoplastic leachates are readily taken up by murine macrophages without any preconditioning, and that short-term microplastic exposure may induce inflammation while exposure to nanoplastic substantially suppressed the lysosomal activities of macrophages. We demonstrated that the ingestion of micro- and nanoplastics released from food containers can exert differential negative effects on macrophage activities, proving that the explosive growth in the use of plastic packaging can poses significant health risks to consumers.


COVID-19 , Water Pollutants, Chemical , Animals , Food Packaging , Humans , Lysosomes , Macrophages , Mice , Microplastics/toxicity , Pandemics , Plastics/analysis , Plastics/toxicity , Water Pollutants, Chemical/analysis
3.
Nature ; 511(7510): 483-7, 2014 Jul 24.
Article En | MEDLINE | ID: mdl-25043018

In mammalian cells, the MYC oncoprotein binds to thousands of promoters. During mitogenic stimulation of primary lymphocytes, MYC promotes an increase in the expression of virtually all genes. In contrast, MYC-driven tumour cells differ from normal cells in the expression of specific sets of up- and downregulated genes that have considerable prognostic value. To understand this discrepancy, we studied the consequences of inducible expression and depletion of MYC in human cells and murine tumour models. Changes in MYC levels activate and repress specific sets of direct target genes that are characteristic of MYC-transformed tumour cells. Three factors account for this specificity. First, the magnitude of response parallels the change in occupancy by MYC at each promoter. Functionally distinct classes of target genes differ in the E-box sequence bound by MYC, suggesting that different cellular responses to physiological and oncogenic MYC levels are controlled by promoter affinity. Second, MYC both positively and negatively affects transcription initiation independent of its effect on transcriptional elongation. Third, complex formation with MIZ1 (also known as ZBTB17) mediates repression of multiple target genes by MYC and the ratio of MYC and MIZ1 bound to each promoter correlates with the direction of response.


Down-Regulation/genetics , Gene Expression Regulation, Neoplastic/genetics , Genes, myc/genetics , Neoplasms/genetics , Transcriptome , Up-Regulation/genetics , Animals , Binding Sites , Cell Line, Tumor , E-Box Elements/genetics , Humans , Kruppel-Like Transcription Factors/metabolism , Mice , Nuclear Proteins/metabolism , Promoter Regions, Genetic/genetics , Protein Inhibitors of Activated STAT/metabolism , Proto-Oncogene Proteins c-myc/genetics , Proto-Oncogene Proteins c-myc/metabolism , RNA Polymerase II/metabolism , Ubiquitin-Protein Ligases
5.
J Toxicol Environ Health A ; 75(8-10): 461-70, 2012.
Article En | MEDLINE | ID: mdl-22686305

The analysis of different variations in genomics, transcriptomics, epigenomics, and proteomics has increased considerably in recent years. This is especially due to the success of microarray and, more recently, sequencing technology. Apart from understanding mechanisms of disease pathogenesis on a molecular basis, for example in cancer research, the challenge of analyzing such different data types in an integrated way has become increasingly important also for the validation of new sequencing technologies with maximum resolution. For this purpose, a methodological framework for their comparison with microarray techniques in the context of smallest sample sizes, which result from the high costs of experiments, is proposed in this contribution. Based on an adaptation of the externally centered correlation coefficient ( Schäfer et al. 2009 ), it is demonstrated how a Bayesian mixture model can be applied to compare and classify measurements of histone acetylation that stem from chromatin immunoprecipitation combined with either microarray (ChIP-chip) or sequencing techniques (ChIP-seq) for the identification of DNA fragments. Here, the murine hematopoietic cell line 32D, which was transduced with the oncogene BCR-ABL, the hallmark of chronic myeloid leukemia, was characterized. Cells were compared to mock-transduced cells as control. Activation or inhibition of other genes by histone modifications induced by the oncogene is considered critical in such a context for the understanding of the disease.


Epigenomics/methods , Genomics/methods , Proteomics/methods , Sequence Analysis, DNA/statistics & numerical data , Algorithms , Animals , Bayes Theorem , Capillary Electrochromatography , Chromatin Immunoprecipitation , DNA/chemistry , DNA/genetics , Data Interpretation, Statistical , Epigenomics/statistics & numerical data , Fusion Proteins, bcr-abl/genetics , Genomics/statistics & numerical data , Hematopoietic Stem Cells/metabolism , Histones/genetics , Histones/metabolism , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Markov Chains , Mice , Microarray Analysis , Models, Statistical , Monte Carlo Method , Oncogenes/genetics , Proteomics/statistics & numerical data , Sample Size , Sequence Analysis, DNA/methods , Transduction, Genetic
6.
Nature ; 483(7391): 608-12, 2012 Mar 28.
Article En | MEDLINE | ID: mdl-22460906

Deregulated expression of the MYC oncoprotein contributes to the genesis of many human tumours, yet strategies to exploit this for a rational tumour therapy are scarce. MYC promotes cell growth and proliferation, and alters cellular metabolism to enhance the provision of precursors for phospholipids and cellular macromolecules. Here we show in human and murine cell lines that oncogenic levels of MYC establish a dependence on AMPK-related kinase 5 (ARK5; also known as NUAK1) for maintaining metabolic homeostasis and for cell survival. ARK5 is an upstream regulator of AMPK and limits protein synthesis via inhibition of the mammalian target of rapamycin 1 (mTORC1) signalling pathway. ARK5 also maintains expression of mitochondrial respiratory chain complexes and respiratory capacity, which is required for efficient glutamine metabolism. Inhibition of ARK5 leads to a collapse of cellular ATP levels in cells expressing deregulated MYC, inducing multiple pro-apoptotic responses as a secondary consequence. Depletion of ARK5 prolongs survival in MYC-driven mouse models of hepatocellular carcinoma, demonstrating that targeting cellular energy homeostasis is a valid therapeutic strategy to eliminate tumour cells that express deregulated MYC.


Gene Expression Regulation, Neoplastic , Genes, myc/genetics , Protein Kinases/metabolism , Repressor Proteins/metabolism , AMP-Activated Protein Kinases/metabolism , Adenosine Triphosphate/metabolism , Animals , Apoptosis , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/genetics , Carcinoma, Hepatocellular/metabolism , Carcinoma, Hepatocellular/pathology , Cell Line, Tumor , Cell Respiration , Cell Survival , Cell Transformation, Neoplastic/genetics , Disease Models, Animal , Doxycycline/pharmacology , Electron Transport , Glutamine/metabolism , Homeostasis , Humans , Liver Neoplasms/drug therapy , Liver Neoplasms/genetics , Liver Neoplasms/metabolism , Liver Neoplasms/pathology , Mechanistic Target of Rapamycin Complex 1 , Mice , Mitochondria/metabolism , Multiprotein Complexes , Oncogene Protein p55(v-myc)/genetics , Oncogene Protein p55(v-myc)/metabolism , Protein Biosynthesis , Protein Kinases/deficiency , Protein Kinases/genetics , Proteins/antagonists & inhibitors , Proteins/metabolism , RNA Interference , Repressor Proteins/antagonists & inhibitors , Repressor Proteins/deficiency , Repressor Proteins/genetics , Signal Transduction , TOR Serine-Threonine Kinases/metabolism
7.
Hepatology ; 45(2): 404-11, 2007 Feb.
Article En | MEDLINE | ID: mdl-17256742

UNLABELLED: The function of Maid (GCIP), a cyclinD-binding helix-loop-helix protein, was analyzed by targeted disruption in mice. We show that Maid function is not required for normal embryonic development. However, older Maid-deficient mice-in contrast to wild-type controls--develop hepatocellular carcinomas. Therefore, we studied the role of Maid during cell cycle progression after partial hepatectomy (PH). Lack of Maid expression after PH was associated with a delay in G1/S-phase progression as evidenced by delayed cyclinA expression and DNA replication in Maid-deficient mice. However, at later time points liver mass was restored normally. CONCLUSION: These results indicate that Maid is involved in G1/S-phase progression of hepatocytes, which in older animals is associated with the development of liver tumors.


Cell Cycle/physiology , Hepatocytes/physiology , Liver/physiology , Transcription Factors/physiology , Adenoma, Liver Cell/pathology , Animals , Carcinoma, Hepatocellular/pathology , Cell Cycle/genetics , Cell Differentiation/genetics , Cell Differentiation/physiology , Cell Division/genetics , Cell Division/physiology , Embryonic Development/genetics , Embryonic Development/physiology , Female , Hepatocytes/cytology , Liver/cytology , Liver/embryology , Liver Neoplasms/pathology , Liver Regeneration/physiology , Male , Mice , Mice, Knockout , Mutation/genetics , Pregnancy , Transcription Factors/genetics
8.
Hepatology ; 44(1): 164-73, 2006 Jul.
Article En | MEDLINE | ID: mdl-16799991

Cyclin E1 controls G1/S phase transition of the eukaryotic cell cycle. We report the impact of alternative spliced cyclin E1 isoforms on cell cycle regulation in hepatocytes. We show that expression of new cyclin E1 mRNA variants IN3, Delta4, and Delta5 is associated with retarded proliferation in murine hepatocellular carcinoma. Additionally, we demonstrate that a new cyclin E1 isoform Delta3/8 lacking the central part of wild-type mRNA is expressed predominantly in nonproliferating murine hepatocytes. Following partial hepatectomy, Delta3/8 is downregulated when hepatocytes enter the cell cycle from quiescence. The Delta3/8 protein does not exhibit any cyclin box motif but binds cyclin-dependent kinase 2 without stimulating kinase activity. We demonstrate that Delta3/8 lacks any nuclear localization signal and is exclusively located in the cytoplasm. Overexpression of Delta3/8 in cultured cells leads to a delayed G0-G1 transition, indicating that this splice variant helps to maintain a quiescent state of hepatocytes. In conclusion, we identified an isoform of cyclin E1 involved in G0 maintenance and suggest an additional mechanism for cell cycle control.


Cell Cycle/genetics , Cyclin E/genetics , Gene Expression Regulation, Neoplastic , Hepatocytes/pathology , Oncogene Proteins/genetics , RNA, Neoplasm/genetics , Animals , Carcinoma, Hepatocellular/genetics , Carcinoma, Hepatocellular/metabolism , Carcinoma, Hepatocellular/pathology , Cells, Cultured , Hepatocytes/metabolism , Humans , In Vitro Techniques , Liver Neoplasms/genetics , Liver Neoplasms/metabolism , Liver Neoplasms/pathology , Mice , Mice, Transgenic , Reverse Transcriptase Polymerase Chain Reaction
9.
J Hepatol ; 42(5): 666-73, 2005 May.
Article En | MEDLINE | ID: mdl-15826715

BACKGROUND/AIMS: Models of fatty liver diseases and fibrosis suggest a hepatoprotective effect of adiponectin, an adipocyte-derived hormone with antidiabetic, antiobesity, antiatherogenic and anti-inflammatory effects. METHODS: We studied adiponectin serum levels in 111 chronic liver disease (CLD) patients and 226 healthy controls and the impact of cholestasis on adiponectin by bile duct ligation experiments in mice. RESULTS: Adiponectin was significantly elevated in CLD, and correlated with stage of liver cirrhosis, liver cell injury, e.g. aminotransferase activity, and inflammatory markers, but not with liver synthesis capacity, insulin sensitivity (HOMA index) or clinical complications. As patients with biliary liver diseases and cholestasis exhibited the highest adiponectin levels, we experimentally investigated a potential biliary route of adiponectin excretion. Following bile duct ligation in mice adiponectin levels rapidly increased without affecting hepatic adiponectin gene expression. Also, adiponectin was detectable in human bile. High adiponectin concentrations were associated with severe cholangitis and/or cholestasis on liver histology. CONCLUSIONS: Adiponectin is elevated in chronic liver disease and correlates with inflammation and liver damage. High adiponectin levels after bile duct ligation in mice and in human bile from cholestatic patients suggest that biliary secretion is involved in adiponectin clearance and that adiponectin could serve as a novel marker indicating cholestasis in liver cirrhosis.


Bile/metabolism , Cholestasis/blood , Hepatitis, Chronic/blood , Intercellular Signaling Peptides and Proteins/blood , Adiponectin , Adolescent , Adult , Aged , Animals , Biomarkers/blood , Cholestasis/complications , Disease Models, Animal , Female , Gene Expression , Hepatitis, Chronic/complications , Humans , Insulin Resistance , Intercellular Signaling Peptides and Proteins/genetics , Ligation , Liver/physiology , Liver Function Tests , Male , Mice , Middle Aged
10.
J Clin Invest ; 115(4): 860-9, 2005 Apr.
Article En | MEDLINE | ID: mdl-15761498

Increasing evidence demonstrates that IL-6 has a protective role during liver injury. IL-6 activates intracellular pathways via the gp130 receptor. In order to identify IL-6-gp130 pathways involved in mediating liver protection, we analyzed hepatocyte-specific gp130 knockout mice in a concanavalin A-induced (Con A-induced) model of immune-mediated hepatitis. We demonstrated that IL-6-gp130-dependent pathways in hepatocytes alone are sufficient for triggering protection in Con A-induced hepatitis. gp130-STAT3 signaling in hepatocytes mediates the IL-6-triggered protective effect. This was demonstrated by analysis of IL-6-induced protection in mice selectively deficient for gp130-dependent STAT1/3 or gp130-SHP2-RAS signaling in hepatocytes. To identify IL-6-gp130-STAT1/3 dependently expressed liver-protective factors, we performed gene array analysis of hepatic gene expression in hepatocyte-specific gp130(-/-) mice as well as in gp130-STAT1/3- and gp130-SHP2-RAS-MAPK-deficient mice. The mouse IL-8 ortholog KC (also known as Gro-alpha) and serum amyloid A2 (SAA2) was identified as differentially IL-6-gp130-STAT3-regulated genes. Hepatic expression of KC and SAA2 mediate the liver-protective potential of IL-6, since treatment with recombinant KC or serum SAA2 effectively reduced liver injury during Con A-induced hepatitis. In summary, this study defines IL-6-gp130-STAT3-dependent gene expression in hepatocytes that mediates IL-6-triggered protection in immune-mediated Con A-induced hepatitis. Additionally, we identified the IL-6-gp130-STAT3-dependent proteins KC and SAA2 as new candidates for therapeutic targets in liver diseases.


Antigens, CD/metabolism , DNA-Binding Proteins/metabolism , Hepatocytes/physiology , Interleukin-6/metabolism , Liver/pathology , Membrane Glycoproteins/metabolism , Signal Transduction/physiology , T-Lymphocytes/metabolism , Trans-Activators/metabolism , Animals , Antigens, CD/genetics , Concanavalin A/toxicity , Cytokine Receptor gp130 , DNA-Binding Proteins/genetics , Enzyme Activation , Extracellular Signal-Regulated MAP Kinases/metabolism , Gene Expression Profiling , Hepatitis/immunology , Interferon-gamma/metabolism , Liver/cytology , Liver/drug effects , Liver/metabolism , Male , Membrane Glycoproteins/genetics , Mice , Mice, Inbred BALB C , Mice, Knockout , STAT1 Transcription Factor , STAT3 Transcription Factor , Serum Amyloid A Protein/metabolism , Trans-Activators/genetics , Tumor Necrosis Factor-alpha/metabolism
11.
J Clin Invest ; 115(4): 849-59, 2005 Apr.
Article En | MEDLINE | ID: mdl-15776110

The inhibitor of NF-kappaB (I-kappaB) kinase (IKK) complex consists of 3 subunits, IKK1, IKK2, and NF-kappaB essential modulator (NEMO), and is involved in the activation of NF-kappaB by various stimuli. IKK2 or NEMO constitutive knockout mice die during embryogenesis as a result of massive hepatic apoptosis. Therefore, we examined the role of IKK2 in TNF-induced apoptosis and ischemia/reperfusion (I/R) injury in the liver by using conditional knockout mice. Hepatocyte-specific ablation of IKK2 did not lead to impaired activation of NF-kappaB or increased apoptosis after TNF-alpha stimulation whereas conditional NEMO knockout resulted in complete block of NF-kappaB activation and massive hepatocyte apoptosis. In a model of partial hepatic I/R injury, mice lacking IKK2 in hepatocytes displayed significantly reduced liver necrosis and inflammation than wild-type mice. AS602868, a novel chemical inhibitor of IKK2, protected mice from liver injury due to I/R without sensitizing them toward TNF-induced apoptosis and could therefore emerge as a new pharmacological therapy for liver resection, hemorrhagic shock, or transplantation surgery.


Apoptosis/physiology , Hepatocytes/drug effects , Hepatocytes/physiology , Protein Serine-Threonine Kinases/metabolism , Protein Subunits/metabolism , Reperfusion Injury , Tumor Necrosis Factor-alpha/pharmacology , Animals , Cells, Cultured , Concanavalin A/pharmacology , Hepatocytes/cytology , I-kappa B Kinase , Liver/cytology , Liver/pathology , Liver/physiology , Male , Mice , Mice, Knockout , Multiprotein Complexes , NF-kappa B/metabolism , Nitric Oxide Synthase/metabolism , Nitric Oxide Synthase Type II , Protein Serine-Threonine Kinases/antagonists & inhibitors , Protein Serine-Threonine Kinases/genetics , Protein Subunits/genetics
12.
Proc Natl Acad Sci U S A ; 101(29): 10608-13, 2004 Jul 20.
Article En | MEDLINE | ID: mdl-15249655

Genetic analysis in mice has demonstrated a crucial role of the Met tyrosine kinase receptor and its ligand, hepatocyte growth factor/scatter factor (HGF/SF), in development of the liver, muscle, and placenta. Here, we use conditional mutagenesis in mice to analyze the function of Met during liver regeneration, using the Mx-cre transgene to introduce the mutation in the adult. After partial hepatectomy in mice carrying the Mx-cre-induced Met mutation, regeneration of the liver is impaired. Comparison of signal transduction pathways in control and mutant livers indicates that Met and other signaling receptors cooperate to fully activate particular signaling molecules, for instance, the protein kinase Akt. However, activation of the Erk1/2 kinase during liver regeneration depends exclusively on Met. Signaling crosstalk is thus an important aspect of the regulation of liver regeneration. Analysis of cell cycle progression of hepatocytes in conditional Met mutant mice indicates a defective exit from quiescence and diminished entry into S phase. Impaired liver regeneration is accompanied by compensatory physiological responses that include prolonged up-regulation of HGF/SF and IL-6 in peripheral blood. Our data demonstrate that the HGF/SF/Met signaling system is essential not only during liver development but also for the regeneration of the organ in the adult.


Liver Regeneration , Proto-Oncogene Proteins c-met/metabolism , Signal Transduction/physiology , Animals , Cell Cycle/physiology , Cell Cycle Proteins/metabolism , DNA-Binding Proteins/metabolism , Glycogen Synthase Kinase 3/metabolism , Glycogen Synthase Kinase 3 beta , Hepatectomy , Hepatocyte Growth Factor/blood , Interleukin-6/blood , Liver/cytology , Liver/metabolism , Liver/pathology , Mice , Mice, Transgenic , Mitogen-Activated Protein Kinases/metabolism , Mutation , Protein Serine-Threonine Kinases/metabolism , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-akt , Proto-Oncogene Proteins c-met/genetics , STAT3 Transcription Factor , Trans-Activators/metabolism , Transgenes
13.
Gastroenterology ; 125(2): 532-43, 2003 Aug.
Article En | MEDLINE | ID: mdl-12891556

BACKGROUND & AIMS: Interleukin 6 (IL-6) contributes via its signal transducer gp130 to the acute phase response (APR) in hepatocytes. Recent studies indicated that IL-6 is involved in the regulation of different pathophysiologic conditions of the liver. To define the IL-6-dependent intracellular pathways more specifically, we generated a hepatocyte-specific gp130 knockout mouse. METHODS: Hepatocyte-specific gp130-deficient mice were generated using the Cre-loxP system. Expression of the Cre recombinase was under the control of a hepatocyte-specific control element. Adult mice were challenged with IL-6, oncostatin M (OSM), and LPS. RESULTS: Cre expression started at day 10.5 postconception, and a complete deletion of gp130 in hepatocytes was found at day 14 during liver development. The adult liver of these mice showed no abnormalities; however, after IL-6 and OSM stimulation, gp130-dependent pathways (STAT3, APR gene expression) were completely blocked in the liver of these animals. Additionally, challenging hepatocyte-specific gp130 knockout animals with lipopolysaccharides (LPS) lead to an onset of acute liver injury with an increase of hepatocyte apoptosis associated with elevated tumor necrosis factor alpha (TNF-alpha) serum levels and reduced nuclear factor kappaB (NF-kappaB) activation in hepatocytes. CONCLUSIONS: Our findings demonstrate that gp130 is of minor relevance for embryonal development of hepatocytes. However, the molecule has an essential role in controlling acute phase gene expression and provides hepatocellular protection after LPS challenge.


Antigens, CD/physiology , Hepatocytes/chemistry , Membrane Glycoproteins/physiology , Animals , Antigens, CD/analysis , Apoptosis , Cytokine Receptor gp130 , DNA-Binding Proteins/metabolism , Gene Expression Regulation , Hepatocytes/pathology , Interleukin-6/genetics , Lipopolysaccharides/pharmacology , Liver/embryology , Male , Membrane Glycoproteins/analysis , Mice , Mice, Knockout , NF-kappa B/metabolism , STAT3 Transcription Factor , Trans-Activators/metabolism , Tumor Necrosis Factor-alpha/genetics
14.
Eur J Immunol ; 33(8): 2251-61, 2003 Aug.
Article En | MEDLINE | ID: mdl-12884300

ME3738 is a new compound that attenuates liver disease in several models of acute and chronic liver inflammation. We used the concanavalin A (Con A) model to elucidate the molecular mechanisms of ME3738 to block liver cell damage. Pretreatment of BALB/c mice with ME3738 prior to Con A injection resulted in a significant reduction in liver injury. The protective effect of ME3738 prior to Con A injection was associated with a reduction in IL-6 serum levels and NF-kappaB DNA binding in liver nuclear extracts. However, STAT3 DNA binding was induced via ME3738 prior to Con A injection. Further analysis showed that ME3738 induces IL-6 serum levels and activates STAT3 DNA binding and target gene transcription. The relevance of this finding was assessed in IL-6(-/-) mice. In these animals, ME3738 induced no increase in IL-6 serum expression, and activation of IL-6-dependent pathways was not found. In addition, ME3738 did not protect IL-6(-/-) animals from Con A-induced liver failure, while IL-6 injection was still effective. Therefore, we demonstrate that ME3738 triggers IL-6 expression, which activates pathways that are relevant to protect from Con A-induced liver failure.


Immunosuppressive Agents/pharmacology , Interleukin-6/metabolism , Liver Failure/immunology , Liver Failure/prevention & control , Oleanolic Acid/analogs & derivatives , Oleanolic Acid/pharmacology , Acute-Phase Reaction/genetics , Acute-Phase Reaction/immunology , Animals , Concanavalin A/toxicity , DNA-Binding Proteins/metabolism , Gene Expression/drug effects , Immunosuppressive Agents/chemistry , Interleukin-6/deficiency , Interleukin-6/genetics , Liver Failure/chemically induced , Liver Failure/pathology , Male , Mice , Mice, Inbred BALB C , Mice, Knockout , NF-kappa B/metabolism , Oleanolic Acid/chemistry , STAT3 Transcription Factor , Trans-Activators/metabolism , Tumor Necrosis Factor-alpha/metabolism
15.
Oncogene ; 22(28): 4380-8, 2003 Jul 10.
Article En | MEDLINE | ID: mdl-12853974

Several growth factors have been suggested to play a crucial role in liver regeneration, but a functional proof is still missing. Since fibroblast growth factors are important for the initiation of mammalian liver development, we determined the roles of these mitogens in liver repair by targeted expression of a dominant-negative fibroblast growth factor receptor (FGFR) in hepatocytes of transgenic mice. The liver of young animals appeared histologically normal, and liver function was not obviously impaired. In aged transgenic mice, the frequency of fatty liver development was strongly increased compared to control animals. Following partial hepatectomy, transgenic mice showed markedly reduced hepatocyte proliferation because of an arrest in the late G(1) phase of the cell cycle. These data demonstrate a key role of FGFR signalling in repair after liver injury.


Liver Regeneration/physiology , Receptor Protein-Tyrosine Kinases/physiology , Receptors, Fibroblast Growth Factor/physiology , Animals , Bromodeoxyuridine/metabolism , Cell Division , Fatty Liver/etiology , G1 Phase , Hepatectomy , Hepatocytes/physiology , Homeostasis , Liver/metabolism , Mice , Mice, Transgenic , Receptor, Fibroblast Growth Factor, Type 2
16.
Gastroenterology ; 125(1): 9-18, 2003 Jul.
Article En | MEDLINE | ID: mdl-12851866

BACKGROUND & AIMS: Hepatitis B virus (HBV) causes acute and chronic infections that may result in severe liver diseases. Animal models to study new treatment options in vivo have several drawbacks. Therefore, we were interested to establish a new small animal model in which HBV replication and especially new treatment options can be studied easily. METHODS: Naked DNA of an HBV replication competent vector was transferred via tail vein into NMRI mice. HBV replication was studied in serum and liver of the animals. HBV replication was modulated by treatment through siRNA and nucleoside analogues. RESULTS: Tail vein transfer of a HBV replication competent construct resulted in expression of HBV-specific transcripts in the liver, and up to 10% of hepatocytes became HBc- and HBsAg-positive. HBeAg, HBsAg, and viral DNA could be detected in the serum of the animals, followed by the induction of HBV-specific cellular immune responses. Nucleoside treatment of the mice resulted in reduced polymerase activity in the liver. Additionally, siRNA transfer in the animals led to a significant reduction of HBsAg and/or eventually HBeAg expression, which was dependent on the localization of the complementary sequence in the HBV genome. CONCLUSIONS: We have established a mouse model to study HBV replication and to investigate new and existing treatment approaches in vivo. Interestingly, siRNA seems a promising innovative treatment option to inhibit specifically HBV replication in vivo.


Genetic Therapy/methods , Hepatitis B virus/growth & development , Hepatitis B/drug therapy , Organophosphonates , RNA, Small Interfering/pharmacology , Adenine/analogs & derivatives , Adenine/pharmacology , Animals , Capsid , Combined Modality Therapy , Disease Models, Animal , Gene Expression Regulation, Viral , Hepatitis B Surface Antigens/blood , Hepatitis B Surface Antigens/genetics , Hepatitis B e Antigens/blood , Hepatitis B e Antigens/genetics , Hepatitis B virus/genetics , Lamivudine/pharmacology , Liver/virology , Male , Mice , Mice, Inbred Strains , Reverse Transcriptase Inhibitors/pharmacology , Specific Pathogen-Free Organisms , Virus Replication
17.
Hepatology ; 38(1): 218-29, 2003 Jul.
Article En | MEDLINE | ID: mdl-12830005

The contribution of the acute phase inducer interleukin 6 (IL-6) in the pathogenesis of liver diseases is yet unclear. Our analysis showed enhanced expression of IL-6 in livers derived from patients with acute and chronic liver diseases. Additionally, IL-6 plasma levels were significantly increased in patients with chronic liver diseases and showed an inverse correlation with biochemical markers of liver function and a positive correlation with inflammatory markers, signs of portal hypertension, and the degree of liver fibrosis. To prove the relevance of these clinical findings, we applied the tetrachlorcarbonide (CCl(4)) model to conditional knockout animals (Cre/loxP system) for gp130, the common signal transducer of IL-6 family cytokines. Cre recombinases were expressed through a hepatocyte (AlfpCre) and a ubiquitous (MxCre) control element. Gp130 deleted mice had a totally abolished STAT3 activation and acute phase response induction, but gp130 deletion had no effect on the degree of acute liver injury and subsequent hepatocyte proliferation. In contrast, during chronic liver injury induced by biweekly application of CCl(4), deletion of the gp130 receptor in nonparenchymal liver cells and not hepatocytes resulted in fibrosis progression. In conclusion, our experiments indicate an involvement of IL-6 in the pathogenesis of liver diseases and suggest a protective role of IL-6/gp130-dependent pathways in nonparenchymal liver cells during fibrosis progression in chronic liver diseases. (Hepatology 2003;38:218-229).


Antigens, CD/metabolism , Interleukin-6/blood , Liver Cirrhosis/metabolism , Liver Failure/metabolism , Membrane Glycoproteins/metabolism , Acute Disease , Adolescent , Adult , Aged , Animals , Antigens, CD/genetics , Carbon Tetrachloride , Cell Division/physiology , Chronic Disease , Cytokine Receptor gp130 , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Disease Models, Animal , Disease Progression , Female , Gene Expression , Hepatocytes/cytology , Humans , Integrases/genetics , Integrases/metabolism , Interleukin-6/genetics , Liver/physiology , Liver Cirrhosis/chemically induced , Liver Cirrhosis/physiopathology , Liver Failure/chemically induced , Liver Failure/physiopathology , Male , Membrane Glycoproteins/genetics , Mice , Mice, Knockout , Middle Aged , STAT3 Transcription Factor , Trans-Activators/genetics , Trans-Activators/metabolism , Viral Proteins/genetics , Viral Proteins/metabolism
...